Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice
Open Access
- 9 February 2021
- journal article
- letter
- Published by Springer Science and Business Media LLC in Blood Cancer Journal
- Vol. 11 (2), 1-4
- https://doi.org/10.1038/s41408-021-00420-8
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinaseLeukemia Research, 2020
- Current Treatment Options for Chronic Myeloid Leukemia Patients Failing Second-Generation Tyrosine Kinase InhibitorsJournal of Clinical Medicine, 2020
- Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND studyLeukemia, 2020
- Expert opinion—management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitorsLeukemia, 2020
- Tyrosine Kinase Inhibitors Available for Chronic Myeloid Leukemia: Efficacy and SafetyFrontiers in Oncology, 2019
- Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trialBlood, 2018
- The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1Nature, 2017
- Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid LeukemiaThe New England Journal of Medicine, 2017
- Identification, prevention and management of cardiovascular risk in chronic myeloid leukaemia patients candidate to ponatinib: an expert opinionAnnals of Hematology, 2016
- Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapyBlood, 2010